Basecamp Research said Wednesday it has raised $140 million in a Series C funding round that valued the AI-based drug developer at $800 million, Reuters reported from Bengaluru.
The oversubscribed round was led by S32, with participation from Nvidia, Anthropic’s Anthology Fund, Catalio Capital Management, the NATO Innovation Fund, the Rockefeller Foundation, and Singular, among other investors. The London-based company previously raised $60 million in a Series B led by Singular in October 2024.
Basecamp said it will use the latest funding to train a new generation of its EDEN biological foundation models and move a pipeline of AI-designed therapies toward clinical development. The company will initially focus on therapies that reprogram patients’ cells inside the body. It said EDEN technology could make cell therapies more customizable and easier to administer for cancer and autoimmune diseases than current treatments it described as costing hundreds of thousands of dollars per patient.
EDEN is trained on Basecamp’s proprietary genomic dataset, assembled through partnerships in more than 30 countries, and can generate potential drug candidates based on information about a disease, the company said. Basecamp added it had demonstrated strong preclinical results across several types of therapies and diseases, but did not provide a timeline for starting clinical trials.
Separately, the company appointed former Biogen executive Richard Pearce as chief business officer to expand pharmaceutical partnerships.
This brief covers Basecamp’s Series C raise and stated plans to train EDEN models and advance AI-designed cell therapies toward the clinic. It does not cover clinical protocols, manufacturing methods, or other lab-process detail.